Clinical Trial · NCT01207895

Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer

Overview

The purpose of this study is to determine if positron emission tomography (PET) imaging with an imaging agent called 18F-fluorodeoxythymidine(\[18F\]-FLT) will allow investigators to measure how well tumor(s) respond to treatment without taking a tissue sample (biopsy). Additionally, the investigators want to determine if it is possible to predict how well tumor(s) might respond to treatment with \[18F\]-FLT PET imaging.

Sponsor

Vanderbilt-Ingram Cancer Center

Phase

Phase 1

Contacts

Henry Manning, Ph.D. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01207895

Drug / Compound

fluorodeoxythymidine

Isotope(s):

Target(s):

cytosolic thymidine kinase 1

Ligand Class: Small Molecules

Eligibility

Inclusion

Subjects with known rectal cancer.
Subjects must have signed an approved consent form.

Exclusion

Patients who are acutely ill who are deemed by their treating physician as not suitable candidates for this study
Children less than 18 are excluded.
Pregnant women and women who are breast feeding will be excluded from this study. A serum beta HCG will also be performed for each pre-menopausal female subject.